We appreciate the thoughtful comments of T.R. Meling and the support of a constructive strategy regarding unruptured brain AVM. The results of the ARUBA trial have been widely commented on and the weaknesses of the study have been pointed out, i.e., the lack of differentiation between Spetzler-Martin grades and treatment modalities, and the fact that the effect of microsurgical removal was not assessed by the study design [4, 8, 9] . The report of the Scottish Audit of Intracranial Vascular Malformations drew less attention, but provided essentially the same result that intervention led to a worse outcome compared to the natural history [1] . The results of ARUBA and the Scottish Audit of Intracranial Vascular Malformations showed an almost identical pattern of strokes following intervention, with initially a higher rate of events than in untreated patients and secondary regression to the rate of the natural history. Therefore, we have to accept that the way we have been treating unruptured AVM was not right and needs correction.
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As pointed out by Meling, the treatment-associated morbidity rates as given in the ARUBA trial, and also the Scottish Audit, are very different from the rates given in microsurgical series. The high morbidity rates of ARUBA and the Scottish Audit are the footprint of destabilized and incompletely eliminated AVM, i.e., the pattern of endovascular embolization [19] . Without any doubt, radiosurgery contributed to the continuing stroke rate in the interventional cohorts but was unlikely a major factor for the increased rate following intervention.
Despite the obvious pattern of the delayed hemorrhages in the ARUBA and the Scottish Audit cohorts, questions remain. All non-randomized series provided rates of stroke after microsurgery, radiosurgery, and embolization far below the 9-10 % per year rate of ARUBA and the Scottish Audit. Probability of hemorrhage after successful microsurgery appears, however, to be approximately one-tenth the rate after endovascular embolization, according to the meta-analysis of van Beijnum [19] . Although the numbers of hemorrhages given in nonrandomized series remain far below the incidence rates in ARUBA and the Scottish cohort, it appears likely that endovascular therapy was the primary factor for the exorbitant event rate following intervention. Analyzing all published series, van Beijnum and coworkers found reported annual hemorrhage rates of 0.18 % after microsurgery 1.7 % after stereotactic radiosurgery and 1.7 % after embolization. The obvious destabilizing effect resulting from treatment as seen in the ARUBA and Scottish Audit cohorts is hardly explainable by radiosurgery.
Endovascular intranidal embolization emerged in the 1980s as a minimally invasive alternative to surgical elimination. It was soon realized, however, that complete elimination could not be routinely achieved. The introduction of Onyx, offering more controllable intranidal dispersion, did not change the picture fundamentally, achieving complete elimination in maximally 50 % [5, 13, 16] . Embolization also remained associated with substantial complications despite technical advances. The rate of resulting morbidity or death is given in most recent series in the range of 10 % [6, 13, 18] . Furthermore, the risk of incompletely embolized AVM remains unclear on the basis of monocentric series. Lasjaunias and collaborators suggested that partial occlusion still reduced the risk of hemorrhage [7] . This concept justified to continue relatively uncritically with embolization as a stand-alone therapy for ruptured and unruptured AVM. During recent years, however, there has been a silent retreat of endovascular therapy as a stand-alone management of brain AVM. While in 2014 almost 40 publications on stereotactic radiosurgery for AVM are listed in PubMed, some 20 on microsurgical resection, less than ten publications focus on endovascular treatment. In comparison, PubMed listed more than 20 publications on endovascular treatment in 2005, while reports on microsurgical resection were similar to 2014 and papers on stereotactic radiosurgery were less than 20.
What remains is the supportive function of endovascular therapy prior to surgery. There is no doubt that endovascular therapy was a major technical advance in the treatment of high-grade AVM. The surgical case fatality rate for brain AVM was in the range of 15 % prior to introduction of endovascular therapy and has decreased to almost zero since [12, 19] . Complex Spetzler-Martin grade 3 and 4 AVMs (corresponding to the recently introduced Spetzler-Ponce classes B and C) have become manageable with the introduction of endovascular therapy as a preparatory adjunct for subsequent microsurgical removal [14] .
Regarding presurgical embolization, surgeons have become more cautious. Endovascular embolization is not innocent. Published combined procedural morbidity and mortality rates are reported around 10 % also in the more recent series [2, 6, 13, 17, 18] . It is unclear whether the risk of subsequent surgical resection decreases correspondingly. Many of us have adopted a policy of routine embolization as the first step and reserving additional microsurgery or stereotactic radiosurgery in case of incomplete endovascular obliteration. Neurosurgeons were usually very willing to accept routine preoperative embolization due to its promise to render microsurgery easier and safer, but even this concept needs to be critically re-evaluated based on current evidence. Prior work by the group of one of us described surgical problems following arterial embolization with resulting congestion of the nidus [15] , and Morgan and coworkers recently found no positive effect of preoperative embolization on surgical outcome [10] . Based on current evidence, endovascular embolization can therefore not be recommended as a preoperative adjunct for Spetzler-Martin grade 1 and 2 AVMs (corresponding to Spetzler-Ponce class A).
Delayed obliteration of AVM following stereotactic radiosurgery contributed to the continuing stroke rate after intervention in the ARUBA trial and the Scottish Audit. Annual hemorrhage rates after radiosurgery have been reported on the average as 1.7 % [19] , therefore not significantly accounting for the 9-10 % per year stroke rate during the first 4 years in the Scottish Audit and ARUBA. Nonetheless, the position of stereotactic radiosurgery remains open at the present time. ARUBA was not designed to grasp a potential benefit of this mode of treatment because of the inherent latency of several years. A protective effect becoming visible only after several years must not necessarily be considered negative, as long as the complication rates remain low. Studies with a follow-up of 5-20 years will be required in order to judge the position of radiosurgery conclusively.
The recent work of Bervini and colleagues, Nerva and colleagues, as well as the report in the current issue provide sufficient substance to recommend microsurgery to patients with unruptured AVM Spetzler-Martin grade 1 and 2 (corresponding to Spetzler-Ponce class A) [3, 11, 14, 16] . In contrast, treatment of unruptured Spetzler-Martin grade 3 and 4 AVMs needs to be seen critically. Here, any treatment appears to be as risky as or riskier than the natural history. It is important to consider microsurgical treatment of unruptured AVMs Spetzler-Martin grade 1 and 2 as a stand-alone therapy, as it has been recently proposed by Spetzler and his group and by other eminent neurovascular surgeons [10, 14] . Unruptured brain AVM present a substantial burden for patients with a 2.3 % annual risk of rupture resulting with 50 % chance in death or permanent disability. It is necessary, however, to continue microsurgical treatment within a controlled frame, at least with accurate book keeping, in order to obtain firm data regarding risks and benefits.
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